• QuidelOrtho Corporation announced third-quarter 2025 results, reporting sales of US$699.9 million and a net loss of US$733 million, alongside issuing full-year revenue guidance of US$2.68 billion to US$2.74 billion.
• While overall sales levels remained substantial, the scale of net losses highlights ongoing cost pressures and the challenges in offsetting product line discontinuations.
• We'll explore how the widening quarterly net loss and updated 2025 guidance may impact QuidelOrtho's investment narrative and outlook.

Rare earth metals are the new gold rush. Find out which 36 stocks are leading the charge.

QuidelOrtho Investment Narrative Recap

To be a shareholder in QuidelOrtho, you need to believe the company can stabilize its core diagnostics businesses and reignite growth, even as post-pandemic normalization continues to erode high-margin COVID-related sales. The recent third-quarter results, with substantial net losses and continuity in revenue guidance, underscore how margin pressures and product line discontinuations remain the most important risks; they overshadow near-term catalysts and reinforce that the biggest challenge is returning to profitability and sustainable top-line growth.

Among recent announcements, the FDA clearance for the VITROS hs Troponin I Assay stands out, adding credibility to QuidelOrtho’s innovation pipeline. While positive, this regulatory achievement alone does not materially alter the investment thesis given the scale of losses and the urgent need for more diversified revenue streams.

By contrast, investors should be aware that portfolio concentration and discontinued products continue to weigh on both diversification and future earnings potential...

QuidelOrtho's narrative projects $3.0 billion revenue and $17.2 million earnings by 2028. This requires 2.6% yearly revenue growth and a $483.6 million increase in earnings from current earnings of -$466.4 million.

Uncover how QuidelOrtho's forecasts yield a $40.33 fair value, a 90% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members offered fair value estimates ranging from US$40.33 to US$80.35, reflecting a spread of three distinct views. However, the persistent revenue and profitability risks reinforce why opinions on QuidelOrtho’s future can vary sharply, making it essential to weigh different perspectives.

Explore 3 other fair value estimates on QuidelOrtho - why the stock might be worth over 3x more than the current price!

Build Your Own QuidelOrtho Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your QuidelOrtho research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free QuidelOrtho research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate QuidelOrtho's overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
• These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.